You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOxyphenbutazone
Accession NumberDB03585  (EXPT02440)
TypeSmall Molecule
GroupsWithdrawn
DescriptionOxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.
Structure
Thumb
Synonyms
Oxifenbutazona
Oxiphenbutazone
Oxyphenbutazonum
External Identifiers
  • USAF Ge-14
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Oxybutazone Tab 100mgtablet100 mgoralIcn Canada Ltd.1981-12-312005-04-26Canada
Oxyphenbutazone 100mg Tabletstablet100 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
OxyphenbutazoneNot Available
ReozonNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Oxyphenbutazone monohydrate
7081-38-1
Thumb
  • InChI Key: CNDQSXOVEQXJOE-UHFFFAOYSA-N
  • Monoisotopic Mass: 342.157957196
  • Average Mass: 342.395
DBSALT001825
Categories
UNIIA7D84513GV
CAS number129-20-4
WeightAverage: 324.3737
Monoisotopic: 324.147392516
Chemical FormulaC19H20N2O3
InChI KeyInChIKey=HFHZKZSRXITVMK-UHFFFAOYSA-N
InChI
InChI=1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,17,22H,2-3,9H2,1H3
IUPAC Name
4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione
SMILES
CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1
Taxonomy
ClassificationNot classified
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9238
Caco-2 permeable+0.5303
P-glycoprotein substrateNon-substrate0.7216
P-glycoprotein inhibitor INon-inhibitor0.7803
P-glycoprotein inhibitor IIInhibitor0.6587
Renal organic cation transporterNon-inhibitor0.8981
CYP450 2C9 substrateNon-substrate0.6167
CYP450 2D6 substrateNon-substrate0.8844
CYP450 3A4 substrateNon-substrate0.5538
CYP450 1A2 substrateInhibitor0.7253
CYP450 2C9 inhibitorInhibitor0.5
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9035
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6021
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.7686
BiodegradationNot ready biodegradable0.9847
Rat acute toxicity2.9626 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9507
hERG inhibition (predictor II)Non-inhibitor0.924
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral100 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point96 °CPhysProp
water solubility60 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.72HANSCH,C ET AL. (1995)
logS-3.73ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.256 mg/mLALOGPS
logP2.79ALOGPS
logP3.83ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)4.87ChemAxon
pKa (Strongest Basic)-6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area60.85 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity90.74 m3·mol-1ChemAxon
Polarizability35.14 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesS01BC02M01AA03M02AA04
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabOxyphenbutazone may increase the anticoagulant activities of Abciximab.
AcebutololOxyphenbutazone may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Aceclofenac.
AcenocoumarolOxyphenbutazone may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Oxyphenbutazone.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Oxyphenbutazone.
Alendronic acidThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Alendronic acid.
AliskirenOxyphenbutazone may decrease the antihypertensive activities of Aliskiren.
AlprenololOxyphenbutazone may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Oxyphenbutazone.
AmikacinOxyphenbutazone may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideOxyphenbutazone may decrease the antihypertensive activities of Amiloride.
AncrodOxyphenbutazone may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Oxyphenbutazone.
Antithrombin III humanOxyphenbutazone may increase the anticoagulant activities of Antithrombin III human.
ApixabanOxyphenbutazone may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Apremilast.
ArdeparinOxyphenbutazone may increase the anticoagulant activities of Ardeparin.
ArgatrobanOxyphenbutazone may increase the anticoagulant activities of Argatroban.
ArotinololOxyphenbutazone may decrease the antihypertensive activities of Arotinolol.
AtenololOxyphenbutazone may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Oxyphenbutazone.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Oxyphenbutazone.
BalsalazideOxyphenbutazone may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Oxyphenbutazone.
BecaplerminOxyphenbutazone may increase the anticoagulant activities of Becaplermin.
BefunololOxyphenbutazone may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Oxyphenbutazone.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Oxyphenbutazone.
BenoxaprofenThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Benoxaprofen.
BetaxololOxyphenbutazone may decrease the antihypertensive activities of Betaxolol.
BevantololOxyphenbutazone may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Oxyphenbutazone.
BisoprololOxyphenbutazone may decrease the antihypertensive activities of Bisoprolol.
BivalirudinOxyphenbutazone may increase the anticoagulant activities of Bivalirudin.
BopindololOxyphenbutazone may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Oxyphenbutazone.
BufuralolOxyphenbutazone may decrease the antihypertensive activities of Bufuralol.
BumetanideOxyphenbutazone may decrease the diuretic activities of Bumetanide.
BupranololOxyphenbutazone may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Oxyphenbutazone.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Oxyphenbutazone.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Oxyphenbutazone.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Oxyphenbutazone.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Oxyphenbutazone.
CarteololOxyphenbutazone may decrease the antihypertensive activities of Carteolol.
CarvedilolOxyphenbutazone may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Oxyphenbutazone.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Oxyphenbutazone.
CeliprololOxyphenbutazone may decrease the antihypertensive activities of Celiprolol.
CertoparinOxyphenbutazone may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Oxyphenbutazone.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Oxyphenbutazone.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Oxyphenbutazone.
CholestyramineCholestyramine can cause a decrease in the absorption of Oxyphenbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Oxyphenbutazone.
Citric AcidOxyphenbutazone may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Oxyphenbutazone.
ColesevelamColesevelam can cause a decrease in the absorption of Oxyphenbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Oxyphenbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineOxyphenbutazone may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with D-Limonene.
Dabigatran etexilateOxyphenbutazone may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinOxyphenbutazone may increase the anticoagulant activities of Dalteparin.
DanaparoidOxyphenbutazone may increase the anticoagulant activities of Danaparoid.
DaunorubicinOxyphenbutazone may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Deferasirox.
DesirudinOxyphenbutazone may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Oxyphenbutazone.
DextranOxyphenbutazone may increase the anticoagulant activities of Dextran.
Dextran 40Oxyphenbutazone may increase the anticoagulant activities of Dextran 40.
Dextran 70Oxyphenbutazone may increase the anticoagulant activities of Dextran 70.
Dextran 75Oxyphenbutazone may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Oxyphenbutazone.
DicoumarolOxyphenbutazone may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Oxyphenbutazone.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Oxyphenbutazone.
DihydrostreptomycinOxyphenbutazone may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Oxyphenbutazone.
DoxorubicinOxyphenbutazone may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneOxyphenbutazone may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Droxicam.
Edetic AcidOxyphenbutazone may increase the anticoagulant activities of Edetic Acid.
EdoxabanOxyphenbutazone may increase the anticoagulant activities of Edoxaban.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Oxyphenbutazone.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Oxyphenbutazone.
EnoxaparinOxyphenbutazone may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Epirizole.
EpirubicinOxyphenbutazone may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneOxyphenbutazone may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Oxyphenbutazone.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Oxyphenbutazone.
EsmololOxyphenbutazone may decrease the antihypertensive activities of Esmolol.
Etacrynic acidOxyphenbutazone may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Oxyphenbutazone.
Ethyl biscoumacetateOxyphenbutazone may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Oxyphenbutazone.
EtofenamateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Oxyphenbutazone.
Evening primrose oilThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Oxyphenbutazone.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Oxyphenbutazone.
FlunixinThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Oxyphenbutazone.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Oxyphenbutazone.
Fondaparinux sodiumOxyphenbutazone may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Oxyphenbutazone.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Oxyphenbutazone.
FramycetinOxyphenbutazone may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideOxyphenbutazone may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Oxyphenbutazone.
GentamicinOxyphenbutazone may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Haloperidol.
HeparinOxyphenbutazone may increase the anticoagulant activities of Heparin.
HirulogOxyphenbutazone may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with HMPL-004.
HydralazineOxyphenbutazone may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Oxyphenbutazone.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Oxyphenbutazone.
Hygromycin BOxyphenbutazone may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Oxyphenbutazone.
IbuproxamThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Icatibant.
IdarubicinOxyphenbutazone may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Oxyphenbutazone.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Oxyphenbutazone.
IndenololOxyphenbutazone may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Oxyphenbutazone.
IndoprofenThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Oxyphenbutazone.
IsoxicamThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Isoxicam.
KanamycinOxyphenbutazone may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Oxyphenbutazone.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Oxyphenbutazone.
LabetalolOxyphenbutazone may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Oxyphenbutazone.
LepirudinOxyphenbutazone may increase the anticoagulant activities of Lepirudin.
LevobunololOxyphenbutazone may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Oxyphenbutazone.
LithiumThe serum concentration of Lithium can be increased when it is combined with Oxyphenbutazone.
LornoxicamThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Oxyphenbutazone.
LoxoprofenThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Oxyphenbutazone.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Oxyphenbutazone.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Oxyphenbutazone.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Oxyphenbutazone.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oxyphenbutazone.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Oxyphenbutazone.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Oxyphenbutazone.
MesalazineOxyphenbutazone may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Oxyphenbutazone.
MetamizoleThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Oxyphenbutazone.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxyphenbutazone.
MetipranololOxyphenbutazone may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Oxyphenbutazone.
MetoprololOxyphenbutazone may decrease the antihypertensive activities of Metoprolol.
MetrizamideOxyphenbutazone may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Oxyphenbutazone.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Oxyphenbutazone.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Oxyphenbutazone.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Oxyphenbutazone.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Oxyphenbutazone.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Oxyphenbutazone.
NadololOxyphenbutazone may decrease the antihypertensive activities of Nadolol.
NadroparinOxyphenbutazone may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Oxyphenbutazone.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Oxyphenbutazone.
NCX 4016The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with NCX 4016.
NeomycinOxyphenbutazone may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nepafenac.
NetilmicinOxyphenbutazone may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Niflumic Acid.
NimesulideThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nimesulide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Oxyphenbutazone.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Oxyphenbutazone.
OlsalazineOxyphenbutazone may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Oxyphenbutazone.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Oxyphenbutazone.
OrgoteinThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Orgotein.
OtamixabanOxyphenbutazone may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Oxyphenbutazone.
OxprenololOxyphenbutazone may decrease the antihypertensive activities of Oxprenolol.
PamidronateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Parecoxib.
ParomomycinOxyphenbutazone may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololOxyphenbutazone may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateOxyphenbutazone may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Oxyphenbutazone.
PhenindioneOxyphenbutazone may increase the anticoagulant activities of Phenindione.
PhenprocoumonOxyphenbutazone may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Oxyphenbutazone.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxyphenbutazone.
PindololOxyphenbutazone may decrease the antihypertensive activities of Pindolol.
PiretanideOxyphenbutazone may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Oxyphenbutazone.
PlicamycinOxyphenbutazone may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Oxyphenbutazone.
PractololOxyphenbutazone may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Oxyphenbutazone.
ProbenecidThe serum concentration of Oxyphenbutazone can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Propacetamol.
PropranololOxyphenbutazone may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Oxyphenbutazone.
Protein COxyphenbutazone may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeOxyphenbutazone may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with PTC299.
PuromycinOxyphenbutazone may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Oxyphenbutazone.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Oxyphenbutazone.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Oxyphenbutazone.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Oxyphenbutazone.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Oxyphenbutazone.
ReviparinOxyphenbutazone may increase the anticoagulant activities of Reviparin.
RibostamycinOxyphenbutazone may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Risedronate.
RivaroxabanOxyphenbutazone may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Oxyphenbutazone.
SalicylamideThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Oxyphenbutazone.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Oxyphenbutazone.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Oxyphenbutazone.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Oxyphenbutazone.
SeratrodastThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Seratrodast.
SotalolOxyphenbutazone may decrease the antihypertensive activities of Sotalol.
SpectinomycinOxyphenbutazone may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Oxyphenbutazone.
SpironolactoneOxyphenbutazone may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with SRT501.
StreptomycinOxyphenbutazone may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinOxyphenbutazone may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfasalazineOxyphenbutazone may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Oxyphenbutazone.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Oxyphenbutazone.
SulodexideOxyphenbutazone may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Oxyphenbutazone.
TacrolimusOxyphenbutazone may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Oxyphenbutazone.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Oxyphenbutazone.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Oxyphenbutazone.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Oxyphenbutazone.
TenofovirThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Oxyphenbutazone.
TepoxalinThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Oxyphenbutazone.
TiludronateThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tiludronate.
TimololOxyphenbutazone may decrease the antihypertensive activities of Timolol.
TobramycinOxyphenbutazone may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Oxyphenbutazone.
TorasemideOxyphenbutazone may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Oxyphenbutazone.
TranilastThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Oxyphenbutazone.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Oxyphenbutazone.
TriamtereneOxyphenbutazone may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Oxyphenbutazone.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Oxyphenbutazone.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Oxyphenbutazone.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Oxyphenbutazone.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Oxyphenbutazone.
WarfarinOxyphenbutazone may increase the anticoagulant activities of Warfarin.
XimelagatranOxyphenbutazone may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Oxyphenbutazone.
Zoledronic acidThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Zomepirac.
Food Interactions
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Phospholipase a2 activity
Specific Function:
PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Has a preference for arachidonic-containing phospholipids.
Gene Name:
PLA2G2E
Uniprot ID:
Q9NZK7
Molecular Weight:
15988.525 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23